A multi-center, randomized, phase 3 study of iodine I 131 tositumomab therapeutic regimen versus ibritumomab tiuxetan therapeutic regimen for patients with relapsed or transformed follicular non-Hodgkin's lymphoma

Trial Profile

A multi-center, randomized, phase 3 study of iodine I 131 tositumomab therapeutic regimen versus ibritumomab tiuxetan therapeutic regimen for patients with relapsed or transformed follicular non-Hodgkin's lymphoma

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2015

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Ibritumomab tiuxetan
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Jan 2007 Status change
    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top